Depression / MDD — Deal Benchmarks & Valuation
Market Analysis
Depression / MDD is one of the most actively transacted indications in neurology licensing. Phase 2 deals for depression / mdd carry a median total deal value of $2.6B, with upfront payments ranging from $144M to $439M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for depression / mdd licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating